Physician profile
Bethany Claar
NPI 1326450669
$2,627.30
in general payments reported to CMS, 2019-2025
27 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $381 · 2021: $375 · 2022: $263 · 2023: $293 · 2024: $352 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $453.78 | 2019-2025 | |
| Novo Nordisk INC | $388.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $318.25 | 2021-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $303.98 | 2019-2025 | Trelegy Ellipta, Ojjaara, Arexvy |
| Lilly USA, LLC | $143.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.22 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $102.60 | 2019-2021 | |
| Amgen INC. | $92.05 | 2019-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $89.25 | 2019-2023 | Eliquis |
| Astellas Pharma US INC | $85.83 | 2020-2023 | Veozah |
| Exact Sciences Corporation | $74.08 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $62.42 | 2022-2023 | Freestyle Libre 3 |
| Celgene Corporation | $54.22 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $52.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.35 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $33.59 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $28.04 | 2019-2020 | |
| Allergan, INC. | $23.76 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.23 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.79 | 2023 | Aplenzin |
| Kowa Pharmaceuticals America, INC. | $20.37 | 2025 | Zoryve |
| Irhythm Technologies, INC. | $19.55 | 2024 | Zio Xt Patch, Zio Monitor |
| Axonics, INC. | $17.67 | 2024 | Axonics |
| Dexcom, INC. | $15.56 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $13.86 | 2023 | Voquezna |
| Sanofi Pasteur INC. | $13.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Claar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.